MASS MEDICAL ANGELS
(MA2)
Dreavent is honored to collaborate with Mass Medical Angels (MA2), a seed-stage investor group specializing in life sciences and healthcare.
This partnership reflects our shared commitment to fostering innovation and supporting early-stage companies in their quest to revolutionize medical treatments and healthcare solutions. Together, we strive to create impactful change in the industry.
1. Seed Stage
Mass Medical Angels (MA2) is a pivotal organization established to meet the critical need for a dedicated life-science-centric angel group in the New England area, with a particular focus on Boston, a renowned global center for medical innovation.
This initiative arises from the observation that early-stage life science companies often face significant hurdles in obtaining initial funding, despite the region's rich innovative ecosystem. MA2’s foundational goal is to bridge this gap by providing essential financial support and mentoring to foster growth and innovation within the life science community.
2. Transform Ideas
As a specialized seed-stage investor group with a keen focus on life science and healthcare, MA2 aims to transform groundbreaking ideas into tangible clinical solutions.
Their commitment as one of our strategic partners involves leveraging their extensive network and in-depth industry knowledge to achieve exceptional returns. Through this symbiotic relationship, MA2 plays a crucial role in advancing medical innovations, driving forward the development of new therapies and solutions that benefit the wider community.
3. Strategic Investment
MA2's investment strategy is meticulously designed to support early-stage life science companies that are seeking to raise funds between $250K and $3.0M. They offer comprehensive financial backing and mentoring services, aiming to not only achieve superior returns but also to promote sustained clinical innovation.
By collaborating with other Angel Groups and Venture Funds, MA2 can either fully fund or contribute to various funding rounds, focusing on capital-efficient opportunities that are likely to lead to significant increases in company valuation and prevent the dilution of future funding rounds.
4. Key Partners
The effectiveness of MA2 in the life science and healthcare sectors is amplified through strategic partnerships with key industry players like Mintz Levin, Baker Tilly, Mass Medic, Mass Bio, and Gill Fishman Design. These collaborations bring together a rich tapestry of legal, financial, and design expertise, enhancing MA2’s ability to support and propel the life science and healthcare industries.
Through these alliances, MA2 not only extends its impact but also solidifies its position as a cornerstone in the ecosystem of medical and life science innovation, fostering a conducive environment for the growth and success of early-stage companies.